1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, M0
Material disclosure
Leading Orexin Franchise Oveporexton Phase 3 Data & Commercial Readiness World Sleep Congress 2025
Corporate Governance Report July 9, 2025
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 424(b)(2)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Certificate
No filings found
Statement of Changes in Beneficial Ownership
Annual Report of Proxy Voting Record
Quarterly Holdings Report for Institutional Managers
Notice of Proposed Sale of Securities
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Specialized Disclosure Report